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Abstract
Background: Few studies have determined the very long-term mortality risks in adult and childhood-diagnosed
coeliac disease.
Objective: We quantified mortality risks in coeliac disease and determined whether age at diagnosis, or time following
diagnosis, modified these risks.
Methods: Standardised mortality ratios were determined using data from a cohort of 602 coeliac patients assembled
between 1979–1983 from Lothian, Scotland, and followed up from 1970–2016.
Results: All-cause mortality was 43% higher than in the general population. Excess deaths were primarily from haemato-
logical malignancies (standardised mortality ratio, 4.77) and external causes (standardised mortality ratio, 2.62) in adult and
childhood-diagnosed cases respectively. Mortality risks declined steadily with time in adult-diagnosed cases (standardised
mortality ratio, 4.85 in first year compared to 0.97, 25 years post-diagnosis). Beyond 15 years, this group had a significantly
reduced risk of any malignancy (standardised mortality ratio, 0.57 (95% confidence interval: 0.33–0.92)). In contrast, for
childhood-diagnosed cases an increased risk existed beyond 25 years (standardised mortality ratio, 2.24).
Conclusions: Adult-diagnosed coeliac patients have a temporarily increased mortality risk mainly from malignant lymph-
omas and a decreased risk of any malignancy beyond 15 years post-diagnosis. In contrast, childhood-diagnosed cases are at
an increased risk of mortality mainly from external causes, and have long-term mortality risks that requires further
investigation.
Keywords
Coeliac disease, mortality, cohort study, UK study, causes of death
Received: 5 June 2018; accepted: 29 October 2018
Key summary
Established knowledge on subject
. Coeliac disease is associated with increased risk of mortality mainly from specific malignancies.
. Increased mortality risks in coeliac disease are greatest during the first few years of diagnosis.
Significant findings of current study
. Adult-diagnosed coeliac disease patients have no significant excess risk of all-cause mortality beyond
25 years after diagnosis, with the confidence intervals around the standardised mortality ratio excluding
a greater than 25% increase.
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. Adult-diagnosed coeliac disease patients have a reduced risk of death from any malignancy more than
15 years after diagnosis.
. Childhood-diagnosed coeliac disease patients have a long-term mortality risk that merits further
investigation.
Introduction
Coeliac disease (CD) patients are reported to have a
higher mortality risk than the general population,
although the reported magnitude of this increase in
risk varies widely.1–8 There is consensus that these
increased mortality risks are observed predominantly
within a few years of diagnosis (1–4 years).1,4–6 Owing
to limited follow-up, the majority of studies have not
been able to assess whether these risks persist for long
periods (>20 years) after diagnosis. Furthermore, stu-
dies have focused entirely on adults1,4 or included con-
siderably more individuals diagnosed in adulthood
(>85%) than in childhood,3,6,9 with many1,3,4 but not
all9 reporting them to be at an increased risk of mor-
tality primarily from lymphatic malignancies. Only a
few studies3,5 have included children or assessed mor-
tality risks in patients diagnosed in childhood, and
these have been limited by short follow-up times5 and
a focus on inpatients,3 who are more likely to have
worse outcomes.
To our knowledge, the first study to have sufficient
follow-up time to assess the difference in mortality risks
between childhood and adulthood-diagnosed CD and
the long-term trends in these risks was that carried out
by Solaymani-Dodaran et al.10 on a cohort of CD
patients followed up from 1970–2004 (Lothian
cohort). Their finding of an increase in long-term mor-
tality in childhood-diagnosed cases, including an excess
mortality particularly from external causes has not
been corroborated. Evidently, further research is
needed to ascertain the magnitude of mortality risks
associated with the disease and the very long-term
(>20 years) changes in these risks. An additional
10 years of mortality data on the Lothian cohort
enabled us to explore mortality risks further, and with
greater statistical power; we aimed to quantify the over-
all and cause-specific mortality risks in adult and child-
hood-diagnosed CD, and determine whether these risks
persist more than 25 years following diagnosis.
Methods
Study participants
Our cohort consisted of CD cases sourced from the
Lothian region of Scotland between 1979–1983. The
Lothian region comprises the administrative districts
of West, East and Mid-Lothian and the City of
Edinburgh. Its total population in 1979 was estimated
at 764,688.11 Current population estimates indicate
little variation in the population statistics, the most
recent population estimate being 880,000.12
Participants were predominantly resident in the City
of Edinburgh, and were identified through: diagnostic
records of gastrointestinal units; existing histopath-
ology records; 1961–1977 CD admissions recorded in
the Scottish Hospital Inpatient Statistics; a postal
survey of 440 general practitioners; and the region’s
CD patient support group. Further details of the par-
ticipants have been published elsewhere.11,13 We
included all participants with at least one small bowel
biopsy showing abnormalities typical of CD, some of
which were confirmed by a second small bowel biopsy
following a gluten withdrawal or gluten challenge (i.e.
confirmed CD) and some of which were not (i.e. prob-
able CD). Participants were further classified during
enrolment into: childhood-diagnosed (patients diag-
nosed prior to their 15th birthday) and adulthood-diag-
nosed (patients diagnosed on or after their 15th
birthday) CD cases.11
Study design
Follow-up commenced on the later of 1 January 1970
(date of first active tracking of cohort) or the date of
clinical diagnosis until the earliest of loss to follow-up,
death, or 20 October 2016. Given that participants were
recruited into the study between 1979–1983, follow-up
prior to 1979 was retrospective.
Cohort mortality data
Following an initial search of Scottish National Death
Records, participants identified to be alive were flagged
in the National Health Service Central Register. Upon
death, copies of their death certificates were sent to the
study team, who linked information on the underlying
causes of death to the cohort participants. The under-
lying causes of death were coded using the 8th–10th
revisions of the International Classification of
Diseases (ICD).
Population mortality data
Mortality rates were determined by applying popula-
tion mortality estimates for the Lothian region
obtained from the National Records of Scotland12,14
for the years 1974–2016. Population mortality estimates
for the years 1970–1973 and cause-specific death
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estimates for 2016 were unavailable, and were extrapo-
lated from the average mortality estimates for the per-
iods of 1974–1976 and 2013–2015 respectively.
Statistical analysis
Overall and cause-specific mortality. We calculated overall
standardised mortality ratios (SMRs) and their 95%
confidence intervals (CIs) for the total person-years of
follow-up using indirect standardisation, by estimating
the number of deaths expected in this amount of
person-time when age (five-year bands), gender and
year specific mortality rates for the Lothian region
were applied to our cohort. We then determined
cause-specific SMRs for causes of death where we had
population data (Appendix 1), using the same
approach. Overall and cause-specific SMRs were calcu-
lated for the whole cohort and separately for adult and
childhood-diagnosed cases.
Mortality risks by time since diagnosis. To determine
whether mortality risks in the cohort were modified
by the length of time following diagnosis, we calculated
overall SMRs for the following times: first year of diag-
nosis, 0–4 years, 5–9 years, 10–14 years, 15–24 years
and 25 years or more post-diagnosis and cause-specific
SMRs for the following times: <15 years following
diagnosis and 15 years following diagnosis.
Sensitivity analysis. To determine whether conclusions
made were dependent on whether or not CD in the
patient had been confirmed, we carried out a sensitivity
analysis by repeating the analyses in participants with
confirmed CD only.
All analyses were carried out using Stata v. 14.2.
Results
Cohort characteristics
Our cohort consisted of 602 participants diagnosed
with CD between 1943–1983 (Table 1) (we excluded
23 participants from the original cohort of 625, who
had died before our study start date). Of these, 73%
had their diagnosis confirmed by one or more biopsies
following gluten withdrawal or a gluten challenge. 318
(53%) participants were diagnosed as adults at a mean
age of 45 years, and 284 (47%) were diagnosed as chil-
dren at a median age of 1.58 years. Participants con-
tributed to a total follow-up of 19,071 person-years,
with childhood-diagnosed cases accounting for a
greater percentage of the follow-up time (60%). Two
hundred and five (64%) adult-diagnosed cases had died
before the end of the study period compared with 32
(11%) childhood-diagnosed cases.
Overall and cause-specific mortality risks
The causes of deaths analysed and the average ages at
which participants died from these causes are presented
in Figures 1 and 2 respectively. We observed an excess
of 70.8 deaths (237 observed deaths, 166.2 expected
deaths) from all causes in the cohort during the entire
study period (Table 2). This represents a relative excess
mortality risk of 43% in the cohort compared to the
general Lothian population (SMR¼ 1.43; 95% CI
1.25–1.62). Participants diagnosed in childhood had
more than double the risk of dying (SMR¼ 2.11;
95% CI 1.44–2.97) compared with a 36% increase in
risk in those diagnosed in adulthood (SMR¼ 1.36;
95% CI 1.18–1.56).
The overall excess mortality was accounted for at
least in part by lymphatic and haematopoietic tissue
(haematological) malignancies in adulthood-diagnosed
cases, and by accidents, suicides and violence (external
causes) in childhood-diagnosed cases (Figure 1). In
adult cases there were 13 haematological malignancies
(all of which were specifically lymphoma), compared
with 2.7 expected, resulting in an SMR of 4.77 (95%
CI 2.54–8.16). Childhood-diagnosed cases had an
increase in risk of death from external causes
(SMR¼ 2.62; 95% CI 1.05–5.40), haematological
malignancies (SMR¼ 8.03; 95% CI 1.66–23) and cere-
brovascular diseases (SMR¼ 4.42; 95% CI 0.53–16),
although the last of these was not statistically
significant.
Mortality risks by time since diagnosis
Overall, mortality risks for the entire cohort declined
gradually over time (Table 3). This decreasing trend
was driven by the results in adult-diagnosed cases.
The highest mortality risk for this group was observed
in the year following diagnosis (SMR¼ 4.85; 95% CI
2.42–8.68). Within 5–9 years post-diagnosis, the excess
risks had decreased to 49% (SMR¼ 1.49; 95% CI
0.97–2.18). Beyond 25 years after diagnosis, adult-
hood-diagnosed CD patients had no significant excess
risk, with the confidence intervals around the SMR
excluding a greater than 25% increase (SMR¼ 0.97,
95% CI 0.74–1.24). Our analysis of childhood-diag-
nosed cases was somewhat hampered by a small
number of expected deaths during the first 24 years
following diagnosis. However, beyond 25 years after
diagnosis, those diagnosed in childhood had more
than double the mortality risk (SMR¼ 2.24; 95% CI
1.45–3.30).
When cause-specific deaths were analysed in the
whole cohort, it appeared that most of the excess
deaths from the different causes had been accrued
during the first 15 years following diagnosis (Table 4).
Among adult-diagnosed cases, there were significantly
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raised mortality risks in the first 15 years for any malig-
nancy as well as for digestive cancers and haemato-
logical malignancies specifically. In contrast, beyond
15 years there was a modest but statistically significant
decreased risk of mortality from any malignancy
(SMR¼ 0.57; 95% CI 0.33–0.92). In childhood-
diagnosed cases, the majority of deaths in the first
15 years were from external causes (SMR¼ 4.89; 95%
CI 1.01–14). Beyond 15 years, the increased risks from
these causes persisted, although lower than before
(SMR¼ 1.95; 95% CI 0.53–4.98). For this group,
increased mortality beyond 15 years of diagnosis was
strongest for haematological malignancies
(SMR¼ 9.44; 95% CI 1.95–28).
Sensitivity analysis
Restricting the analyses to confirmed cases did
not produce any substantial differences in the esti-
mates obtained (data not shown). We observed a
similar pattern of higher mortality risks in child-
hood-diagnosed cases, as well as a decreasing trend
in mortality risks with increasing time following
diagnosis.
Table 1. Cohort characteristics.
Age at diagnosis
Characteristic <15 years (n¼ 284) 15 years (n¼ 318) Total (n¼ 602)
Number of participants, n (%)
Male 129 (45.42) 105 (33.02) 234 (38.87)
Female 155 (54.58) 213 (66.98) 368 (61.13)
Diagnosis, n (%)
Confirmed 197 (69.37) 242 (76.10) 439 (72.92)
Probable 87 (30.63) 76 (23.90) 163 (27.08)
Age group at diagnosis (years), n (%)
0–4 223 (78.52) – 223 (37.04)
5–9 46 (16.20) – 46 (7.64)
9–14 15 (5.28) – 15 (2.49)
15–24 – 35 (11.01) 35 (5.81)
25–34 – 63 (19.81) 63 (10.47)
35–44 – 60 (18.87) 60 (9.97)
45–54 – 58 (18.24) 58 (9.63)
55–64 – 71 (22.33) 71 (11.79)
65–74 – 27 (8.49) 27 (4.49)
75–84 – 4 (1.26) 4 (0.66)
Age at diagnosis (years)
Mean SD 2.97 3.14 44.99 15.49 25.17 23.92
Median (IQR) 1.58 (0.91–4.21) 45.46 (31.75–58.50) 21.67 (1.67–46.82)
Year of diagnosis, n (%)
Prior to 1970 135 (47.54) 93 (29.25) 228 (37.87)
1970–1983 149 (52.46) 225 (70.75) 374 (62.13)
Status at end of study,a n (%)
Dead 32 (11.27) 205 (64.47) 237 (39.37)
Alive 228 (80.28) 97 (30.50) 325 (53.99)
Censoredb 24 (8.44) 16 (5.03) 40 (6.64)
Follow-up time (person-years)
Total 11,500.79 7570.95 19,071.74
Mean follow-up SD (per person) 40.50 9.87 23.81 15.46 31.68 15.54
IQR: interquartile range; SD: standard deviation.
aEnd of study, 26 October, 2016.
bCensored, lost to follow-up through emigration.
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Discussion
Key findings
People diagnosed with CD were at a 43% increased risk
of mortality compared to the general population. The
largest relative risks of death were from haematological
malignancies (>90% of which were specifically lymph-
oma) in both adult and childhood-diagnosed cases.
Mortality risks declined steadily with time since diag-
nosis, particularly in the adulthood-diagnosed cases.
For these, we observed a lower than expected risk of
mortality from all malignancies after the first 15 years
of diagnosis. We did not have sufficient follow-up at
ages where mortality is expected to be high in the child-
hood-diagnosed cases to be able to make robust con-




















































Figure 2. Average ages at death from specific causes.
Average age of death among participants who died by cause of death.
Childhood-diagnosed cases
(16.8 excess deaths in total)
Adulthood-diagnosed cases














Accident, suicide and violence
Other cause
Figure 1. Proportion of excess deaths from analysed causes.
Causes of death analysed in the cohort and the percentage of excess deaths from each of these causes, calculated as number of excess
deaths from specific cause/total number of excess deaths 100%. Definition of symbols used: *Significant number of excess deaths.
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25 years post-diagnosis, CD patients diagnosed as
adults are no longer at a higher risk of mortality com-
pared to the general population.
Strengths and limitations
Our study can boast a number of strengths, one of them
being that it was population-based and therefore not
prone to selection bias. Another strength is the use of
the generally accepted gold standard15 of biopsies as a
means of confirmation of CD. By using death certifi-
cates to ascertain the underlying causes of death, we
have ensured a uniform quality of recording of causes
of death in the cohort and the general population to
which it was compared. We also have long follow-up,
allowing us to assess longer-term risks, something
impossible for earlier studies.
Supposing that CD truly raises mortality risks,
then our estimates may have been underestimated
by the inclusion of probable cases, if many of these
did not indeed have CD (non-differential misclassifi-
cation). In this instance, restricting the analyses to
confirmed cases would have resulted in higher mor-
tality estimates, at the cost of wider confidence inter-
vals. However, when we restricted the analyses to
confirmed cases, we observed slightly lower mortality
risks and similar trends in all-cause and cause-specific
mortality, implying that our probable cases were
likely to be true CD cases. Given that over 70% of
our cases were confirmed, we are quite confident that
Table 2. Overall and cause-specific standardised mortality ratios (SMRs) by age at diagnosis.
Age at diagnosis
<15 years (n¼ 284) 15 years (n¼ 318) Overall (n¼ 602)
Cause of death Obs Exp SMR (95% CI) Obs Exp SMR (95% CI) Obs Exp SMR (95% CI)
All cause 32 15.20 2.11 (1.44–2.97)a 205 151.02 1.36 (1.18–1.56)a 237 166.22 1.43 (1.25 – 1.62)a
All malignancy 8 3.74 2.14 (0.92–4.21) 50 41.57 1.20 (0.89–1.59) 58 45.32 1.28 (0.97–1.65)
Digestive cancer <5 b 0.00 (0.00–4.53) 16 10.82 1.48 (0.85–2.40) 16 11.63 1.38 (0.79–2.23)
Lymphatic and haematopoietic
tissue malignancy
<5 b 8.03 (1.66–23)a 13 2.73 4.77 (2.54–8.16)a 16 3.1 5.16 (2.95–8.38)a
Breast cancer <5 b 2.69 (0.07–15) <5 b 0.00 (0.00–2.76) <5 b 0.59 (0.01–3.26)
Cerebrovascular disease <5 b 4.42 (0.53–16) 25 19.43 1.29 (0.83–1.90) 27 19.88 1.36 (0.90–1.98)
Ischaemic heart disease <5 b 0.00 (0.00–2.86) 42 35.63 1.18 (0.85–1.59) 42 36.92 1.14 (0.82–1.54)
Accident, suicide and violence 7 2.67 2.62 (1.05–5.40)a <5 b 0.90 (0.24–2.30) 11 7.13 1.54 (0.77–2.76)
CI: confidence interval; Exp: expected deaths; Obs: observed deaths.
ap< 0.05; bIn order to minimise the risk of disclosure of the identity of individual study participants, we have adhered to the rule of thumb suggested by the
Office for National Statistics of suppressing all cell frequencies where the observed cell frequency is less than 5 (‘Review of the Dissemination of Health
Statistics: Confidentiality Guidance: National Statistics; HMSO 2006’).
Table 3. Overall standardised mortality ratios (SMRs) by time since diagnosis.
Age at diagnosis
<15 years (n¼ 284) 15 years (n¼ 318) Total population (n¼ 602)
Time since diagnosis Obs Exp SMR (95% CI) Obs Exp SMR (95% CI) Obs Exp SMR (95% CI)
First year <5 a 0.00 (0.00–9.39) 11 2.27 4.85 (2.42–8.68)b 11 2.66 4.14 (2.06–7.40)b
1–4 years <5 a 0.00 (0.00–2.87) 27 10.74 2.51 (1.66–3.66)b 27 12.03 2.24 (1.48–3.27)b
5–9 years <5 a 11.22 (3.06–29.00)b 26 17.5 1.49 (0.97–2.18) 30 17.86 1.68 (1.13–2.40)b
10–14 years <5 a 2.18 (0.06–12.00) 29 18.57 1.56 (1.05–2.24)b 30 19.03 1.58 (1.06–2.25)b
15–24 years <5 a 1.31 (0.16–4.73) 50 37.93 1.32 (0.98–1.74) 52 39.45 1.32 (0.98–1.72)
25þ years 25 11.18 2.24 (1.45–3.30)b 62 64.01 0.97 (0.74–1.24) 87 75.19 1.16 (0.93–1.43)
CI: confidence interval; Exp: expected deaths; Obs: observed deaths.
aIn order to minimise the risk of disclosure of the identity of individual study participants, we have adhered to the rule of thumb suggested by the Office for
National Statistics of suppressing all cell frequencies where the observed cell frequency is less than 5 (‘Review of the Dissemination of Health Statistics:
Confidentiality Guidance: National Statistics; HMSO 2006’): bp< 0.05.
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the inclusion of probable cases did not affect our
results substantially.
There were other potential limitations. First, around
23% of the study participants lived outside the Lothian
region (Fife or the Scottish borders) when diagnosed
with CD.11 However, the demographic characteristics
and mortality pattern of people living in Fife and the
Scottish borders are generally similar to that of people
in the Lothian region.16 Hence, we do not believe there
are significant differences in the characteristics of the
participants living within and outside the Lothian
region to have rendered the population data used
inappropriate. Second, we were unable to adjust for
the effect of certain factors such as socio-economic
status, smoking, compliance with gluten-free diets
(GFDs), body mass index (BMI), existence of co-mor-
bidities, etc., which may be associated with high mor-
tality risks. Previous studies, however, have found that
adjusting for BMI, smoking6 and education5 did not
remove the effect. Third, approximately half of the
deaths in the cohort were from causes that we did not
have population data on. We are therefore unable to
speculate as to whether people with CD have different
mortality risks from causes of death that we have not
analysed.
Other studies
Overall and cause-specific mortality. The 43% raised mor-
tality risk observed is much lower than most of the
earlier reports1,4 and more in agreement with recent
studies,5,6 which have reported modest increases (30–
40%) in mortality risks in CD patients. This lends sup-
port to the findings of decreased mortality risks with
increasing length of time following diagnosis,4–6 as our
current analysis was based on follow-up data more than
15 years following diagnoses in most cases.
We have just a few studies with which to compare
our findings of higher risks in childhood than adult-
hood-diagnosed cases. While two studies3,5 have simi-
larly reported high risks in children, they either
included young adults5 or had a shorter follow-up
time.3
Our finding of excess risks of death from malignant
lymphomas in adult and childhood-diagnosed CD is
consistent with other studies1,3,4,7 and our previous
observation from this cohort that malignancy itself
was raised in CD patients,17 a finding not supported
by all previous research.18 Previous research has high-
lighted a reduced risk of breast cancer in CD
patients,6,9 however, with only small numbers of
Table 4. Cause-specific standardised mortality ratios (SMRs) by time since diagnosis.
Age at diagnosis
<15 years (n¼ 284) 15 years (n¼ 318) Total population
Period after diagnosis Obs Exp SMR (95% CI) Obs Exp SMR (95% CI) Obs Exp SMR (95% CI)
All malignancy
<15 years <5 a 0.00 (0.00–23) 34 13.47 2.53 (1.75–3.53)b 34 13.62 2.50 (1.73–3.49)b
15 years 8 3.58 2.23 (0.96–4.40) 16 28.11 0.57 (0.33–0.92)b 24 31.69 0.76 (0.49–1.13)
Digestive cancer
<15 years <5 a 0.00 (0.00–780) 12 3.62 3.31 (1.71–5.79)b 12 3.63 3.31 (1.71–5.78)b
15 years <5 a 0.00 (0.00–4.56) <5 a 0.56 (0.15–1.42) <5 a 0.50 (0.14–1.28)
Lymphatic and haematopoietic tissue malignancy
<15 years <5 a 0.00 (0.00–66) 10 0.77 13.04 (6.25–24)b 10 0.82 12.15 (5.83–22)b
15 years <5 a 9.44 (1.95–28)b <5 a 1.53 (0.32–4.48) 6 2.28 2.64 (0.97–5.74)
Cerebrovascular disease
<15 years <5 a 0.00 (0.00–260) 8 6.20 1.29 (0.56–2.54) 8 6.21 1.29 (0.56–2.54)
15 years <5 a 4.56 (0.55–16) 17 13.23 1.29 (0.75–2.06) 19 13.67 1.39 (0.84–2.17)
Ischemic heart disease
<15 years <5 a 0.00 (0.00–3200) 13 14.18 0.92 (0.49–1.57) 13 14.18 0.92 (0.49–1.57)
15 years <5 a 0.00 (0.00–2.86) 29 21.45 1.25 (0.91–1.94) 29 22.74 1.28 (0.85–1.83)
Accident, suicide and violence
<15 years <5 a 4.89 (1.01–14)b <5 a 0.58 (0.01–3.22) <5 a 1.71 (0.47–4.37)
15 years <5 a 1.95 (0.53–4.98) <5 a 1.10 (0.23–3.21) 7 4.79 1.46 (0.59–3.01)
CI: confidence interval; Exp: expected deaths; Obs: observed deaths.
aIn order to minimise the risk of disclosure of the identity of individual study participants, we have adhered to the rule of thumb suggested by the Office for
National Statistics of suppressing all cell frequencies where the observed cell frequency is less than 5 (‘Review of the Dissemination of Health Statistics:
Confidentiality Guidance: National Statistics; HMSO 2006’): bp<0.05.
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deaths (<5) we were unable to say whether this extends
to mortality from breast cancer.
The observed excess deaths in childhood-diagnosed
cases from external causes is consistent with prior pub-
lications from this cohort10,11 and reports of causes of
death in children in the UK and worldwide.19 However,
it is unclear why childhood-diagnosed CD patients
would have significantly more of such deaths than the
general population. According to Cinquetti et al.20 the
acceptance of GFDs in children and adolescents can be
associated with adverse psychological effects such as
depression and anxiety. In addition, there is evidence
that hypervigilance to GFDs may have a negative
impact on quality of life.21 This may therefore make
such individuals more inclined to intentional self-
harm; however, this reasoning is speculative and further
research is needed.
Mortality risks with time following diagnosis. Similar to
most studies,1,4,5,11 we have confirmed that the mortal-
ity risks in CD patients are greatest during the first few
years after diagnosis. It is plausible that at the time of
diagnosis, patients in our cohort (all of whom were
diagnosed prior to 1984) were more symptomatic and
presented with more severe forms of the disease, as has
been hypothesised to be the case with patients diag-
nosed in the pre-serological era.8,22 This coincides
with the recognition that diagnosis at this time was
more difficult than what it has become with serology
and endoscopic biopsy. This is evidenced from co-exist-
ing symptoms at the time of diagnosis among the pre-
sent cohort.23 Another possible explanation is that the
cases may have presented with illnesses other than CD,
leading to an ascertainment bias with respect to CD
diagnosis.
Alternatively, it could be argued that CD patients
adopt healthier lifestyles after their diagnoses and are
therefore less likely to have higher mortality risks than
before. As reported in some studies, CD patients are
generally less likely than the general population to
smoke or be obese6 and, also, they have lower fat
intake and better cholesterol profiles,24,25 all of which
are associated with lower mortality risks.
The reduction in all malignancies in adult cases
15 years following diagnosis is an interesting finding
which needs further exploration through research.
Few studies9,17,26 have reported a decrease in the inci-
dence of malignancies in CD 10 years or more follow-
ing diagnoses, but we are not aware of any study, that
corroborates our finding of decreased mortality risk
from these causes 15 years after diagnosis. The results
may have been driven by a combination of breast
cancer and other cancers sharing similar biological
properties with breast and lung cancers, which some
studies have shown CD patients to be protected
from.6,9 Understanding the mechanism of protection
from these cancers could provide valuable information
on the treatment of cancers in the general population.
The persistent increase in mortality risks in child-
hood-diagnosed cases more than 25 years after diagno-
sis is consistent with the earlier report on the cohort,10
and requires further investigation. A longer follow-up
of these cases will enable a better assessment of the risks
from diseases that occur in later years in life but this
will necessitate several additional decades of follow-up
of this cohort for us to be able to estimate these risks
with sufficient precision. Therefore, retrospectively col-
lected data available from people with childhood-diag-
nosed CD in the distant past is likely to offer our best
hope of realising this.
Mortality risks in the Lothian cohort over time. A summary
of key findings from all mortality follow-up of the
Lothian cohort is provided in Table 5.
Table 5. Summary of key findings from all follow-up of the Lothian cohort.
Study
No.
patients Follow-up time Statistical measure Key findings and comments
Logan et al.11 653 Date of clinical diagno-
sis of CD to 30 June
1986




 Mortality overall was 1.9-fold more for CD
patients than that of the general population.
The SMR was similar in men and women.
 10 deaths were directly attributable to CD, com-
pared to 44 from malignancies (corresponding
SMR of 3.0 fold for malignancies).
 Only four deaths occurred in cases diagnosed in
childhood (aged<15 years, total sample size of
292). All these deaths were from external
causes.
(continued)




patients Follow-up time Statistical measure Key findings and comments
 Overall, there was a gradual decline in SMR with
increased time from diagnosis. For 15þ years,
there was an SMR of 1.2; however, this was




602a Date of clinical diagno-









 All analyses in this paper were presented sep-
arately for child (0–14 years) and adult (15þ
years) diagnosed cases. The overall raised
mortality risk was higher in childhood-diag-
nosed cases (SMR¼ 2.6) than for adult-diag-
nosed cases (SMR¼ 1.6)
 Among childhood-diagnosed cases there were 21
deaths, of which seven were due to external
causes (SMR¼ 2.9) and five due to neoplasms
(SMR¼ 3.6). Both these increases were statis-
tically significant.
 Due to the increased follow-up, the expected
number of deaths 15þ years following diagno-
sis had increased to 68.71. In childhood-diag-
nosed cases there was a raised risk 25þ years
after diagnosis (SMR¼ 3.5). For adult-diag-
nosed cases, no corresponding risk was
observed but the confidence interval was wide
(SMR¼ 1.26; 95% CI 0.86–1.77).
Current study 602 Date of clinical diagno-
sis of CD or 1
January 1970
(whichever was






 In the current study, the overall increase in
mortality was 2.1-fold in childhood-diagnosed
cases and 1.4-fold in adult-diagnosed cases.
The decrease in overall SMRs compared with
the earlier reports reflects the decline in risk
following increased time from diagnosis.
 There were 32 deaths among childhood-diag-
nosed cases, of which the number of deaths
from malignancy increased to eight and the
number from external causes remained at
seven. However, the expected number of deaths
from external causes only increased slightly
compared with the previous report (2.67 vs 2.39)
as childhood-diagnosed participants are now at
an age where deaths attributed to this cause are
less common.
 The expected number of deaths 15þ years fol-
lowing diagnosis has increased to 114.64.
Among adult-diagnosed cases, the absence of
an increased risk beyond 25 years reported
previously remains but the confidence interval
around this value has tightened considerably
(SMR¼ 0.97; (95% CI 0.74–1.24). The equivalent
SMR for childhood-diagnosed cases was
reduced in this updated follow-up (SMR¼ 2.2)
as the impact of deaths from external causes on
this overall figure has been weakened.
 There was a reduced risk of death from any
malignancy more than 15 years after diagnosis
in adult-diagnosed CD patients. Previously
(continued)
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Conclusion
Our study indicates that individuals with CD are at a
modestly increased risk of mortality compared to the
general population. The increased risk, primarily from
malignant lymphomas, is only temporary in adults and
generally declines in the long-term. The increased risk
of death from external causes in childhood-diagnosed
cases which we highlighted in our previous report per-
sisted with this longer-term follow-up and should form
the focus of further research.
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Appendix 1. Causes of death analysed and their corresponding International Classification of
Diseases (ICD) codes
ICD code
Disease group ICD 8 ICD 9 ICD 10
Neoplasms
All malignant neoplasms 140–209 140–209 C00–C97
Malignant neoplasm of lymphoid, haematopoietic and related tissue 200–209 200–209 C81–C96
Malignant neoplasm of breast 174 174–175 C50






Diseases of the circulatory system
Ischaemic heart disease 410–414 410–414 I20–I25
Cerebrovascular disease 430–438 430–438 I60–I69
External causes of morbidity and mortality
Accidentb E800–E929,
E940–E946
E800–E929 V01–X59, Y85, Y86
Intentional self-harm (suicide) E950–E959 E950–E959 X60–X84, Y87.0
Assault (violence) E960–E969 E960–E969 X85–Y09, Y87.1
Event of undetermined intent E980–E989 E980–E989 Y10–Y34, Y87.2
aExcludes malignant neoplasms of small intestine, gall bladder, other and ill-defined digestive organs.
bIncludes transport accidents, falls and poisoning.
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